MMJ Recs

OCTOBER 2, 2023

These cover various aspects, including cultivation, manufacturing, testing, packaging, and labeling of medical cannabis products. These establishments provide a diverse selection of medical cannabis products, including flowers, edibles, tinctures, and topicals.

Dispensary 52

Dispensary Patients Environment Conditions 52

Puff Puff Post

NOVEMBER 5, 2019

INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). With our extensive preclinical development package in hand, we are positioned to efficiently pursue additional indications for INM-755. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

AUGUST 10, 2021

Following the Closing, MTL Cannabis’ wholly owned subsidiaries will hold cultivation, processing, and sales licences for plants/seeds, flower, oil, concentrate, topical and edible products and will have existing supply agreements with nine Canadian provinces including British Columbia, Alberta, Ontario, and Québec. providing approx.

Seed-To-Sale 105

Seed-To-Sale Cultivation Patients Cannabis 105

Cannabis Law Report

SEPTEMBER 20, 2021

Embark is also equipped to produce a range of cannabis concentrates, liquid and powder beverage mixes, topicals and edible products. Embark Delta is federally licensed and is actively producing concentrates, beverage mixes and topicals. – Topicals infused with proprietary pharmaceutical delivery technology. Meridian Co.

Hash 52

Hash Seed-To-Sale Research and Development Topical 52

The Joint Blog

OCTOBER 8, 2021

Even for smaller forms of anxiety such as fear of public speaking, this therapy can be immensely helpful – even reducing symptoms in some participants who experienced relief from their condition after taking 1500mg per day (typically at 10-50mg doses). You can have a look into current CBD studies. .

Vaping 49

Vaping CBD Blood Pressure Chronic Pain 49

Puff Puff Post

NOVEMBER 5, 2019

INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). With our extensive preclinical development package in hand, we are positioned to efficiently pursue additional indications for INM-755. For more information, visit www.inmedpharma.com.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

The Cannigma

FEBRUARY 16, 2022

I love the fact that we’re really starting to lean into this more because I think it’s a topic that deserves attention. CP: Yeah, like my passion is keeping cannabis from going full CPG, consumer packaged goods and keeping medical. So sampling, how did your sample get collected? CP: Catalog, like a magazine?

Trichome 73

Trichome Wellness and Beauty Cannabinoids Cannabis 73